ArticleFrontiers in oncology2022

First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study.

Xiaofen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.